Latest news:
FDA Announces Shift Away from Mandatory Animal Testing – BioReperia Offers a Validated, Human-Relevant Alternative
Read more
Metastasis

An agile & highly customizable
toolbox for drug discovery

Obtain highly translational in-vivo data on the anti-metastatic effect of your compounds in just 5 days.

Zebrafish, metastasis evaluation

How it works

The xenograft is vascularized within 3 days, allowing for tumor cell extravasation, which makes ZTX® an excellent platform for screening metastasis invasion.

Metastasis references
PDX model, xenograft, tumor efficacy, metastasis
ZTX®platform

Our unique ZTX®platform shortening time for drug discovery by providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days

The fast development of the embryo enables rapid vascularization of the developed microtumor, allowing cells to disseminate from the primary tumor site to the vasculature and the surrounding tissues.

Metastatic cells will disseminate from the primary site into the vasculature and to the hematopoietic site in the embryo´s tail, where the metastatic cells will migrate to the tissue.

ZTX®platform

Accelerate the discovery of new therapeutic agents that target cancer metastasis

How it works

  • The fast development of the embryo enables rapid vascularization of the developed microtumor, allowing cells to disseminate from the primary tumor site to the vasculature and to the surrounding tissues.

Output

  • Evaluation of the anti-metastatic efficacy of your drug candidates.
  • The potential of the added compounds to inhibit both local and distal metastasis.

Let us know what you would like to test and we will design the study for you

We have extensive experience working with metastasis models, and our project managers will assist you in planning your study.

ZTX®platform

Screening of constructs

  • Xenografts were generated from a lung cancer PDX model
  • Human PBMC from a healthy donor was intravenously administrated
  • Testing different constructs administered by co-injection with the tumor cells

Constructs were evaluated according to their ability to reduce the tumor size and inhibit metastasis.

Clinical prediction of disease progression

ZTX® is a prognostic tool for validation of Epithelial Ovarian Cancer treatment

Read full text paper Patient metastasis

Study outline

Xenografts were generated from primary biopsies of patients (n=19) with epithelial ovarian cancer and metastatic dissemination was evaluated.

Results

High metastatic dissemination in the ZTX®platform (mets >5) correlated to the development of an advanced disease stage in the patients (orange bars).

Outcome

Tool for health care to predict prognosis and individualize treatment.

This website uses cookies

We use essential cookies to make our website work. With your consent, we also use non-essential cookies to improve the user experience and analyze website traffic. You can change your cookie settings at any time by clicking on Cookie settings..

Which cookies do you want to accept?

This website uses cookies

We use different types of cookies to optimize your experience on our website. Click on the categories below to learn more about their purposes. You can choose which types of cookies to allow and can change your settings at any time. Remember that disabling cookies may affect your experience on the website.

Which cookies do you want to accept?

These cookies are essential for the proper functioning of the website and cannot be disabled.

These cookies collect information about how you use our website. All of the data is anonymized and cannot be used to identify you.

Read more about Google's privacy policy and terms of use